Abstract:Objective To identify the effect of six components of salviae miltiorrhizae on the metabolism of fluvastatin in the human liver microsomes (HLMs) and to further explore the effect of cryptotanshinone and dihydrotanshinone Ⅰ on the metabolism of fluvastatin based on the polymorphism (* 1,* 2,* 3) of cytochrome P450 2C9 (CYP2C9).Methods Establishing the incubation system of HLMs and recombinase and determining the concentration of fluvastatin by HPLC.To calculate the enzyme kinetic parameters,half maximal inhibitory concentration (IC50) and inhibition constant (Ki) so as to compare the impact of different CYP2C9 mutation site on the metabolism of fluvastatin and the influence of components of salviae miltiorrhizae on the metabolism process.Results It was shown that cryptotanshinone and dihydrotanshinone Ⅰ exerted significant inhibition on the metabolism of fluvastatin and the residual activity were 30.24％,14.52％ respectively when the concentrations were 10 μmol · L-1 in the HLMs.However,other exhibited no inhibitory effect.The michaelis constant (Km),maximum velocity (Vmax) and intrinsic clearance (CLint) of CYP2C9 * 1,* 2,* 3 recombinase-catalyzed fluvastatin was (1.56±0.21),(1.79±0.25),(2.32±0.43)μmol· L-1,(41.75±1.67),(26.55±1.08),(12.85±0.79) pmol · min-1 · mg-1 and 26.71,14.86,5.53 μL · min-1 · mg-1 respectively.It was indicated that the metabolic activity of CYP2C9 * 1 was stronger than * 2,* 3.The IC50 value of CYP2C9 * 1,* 2,* 3 recombinase-catalyzed fluvastatin by cryptotanshinone and dihydrotanshinone Ⅰ was (1.74 ± 0.41),(2.64 ± 0.81),(3.17 ± 0.32) μmol · L-1 and (0.19 ±0.09),(0.56 ±0.16),(1.52 ±0.34) μmol · L-1.The IC50 and Ki value of CYP2C9 * 1 was less than * 2 and * 3 but there was statistical significance between the * 1 and * 3 with respect to the difference of IC50 and Ki.Conclusion The mutation site of 430(C ＞ T) and 1075 (A ＞ C) could influence the metabolic activity of CYP2C9.The cryptotanshinone and dihydrotanshinone Ⅰ exerted strong inhibitory effect against CYP2C9 recombinase-catalyzed fluvastatin and their inhibitions on CYP2C9 * 1,* 2,* 3 recombinase-catalyzed fluvastatin were different.

Effects of organic anion transporting polypeptide1B1 and cytochrome P2C9 genetic polymorphism on the transportation of fluvastatin

The Influence of Genetic Polymorphisms in Drug Metabolism Enzymes and Transporters on the Pharmacokinetics of Different Fluvastatin Formulations

The molecular mechanism of actin of OATP1B1 and CYP3A4 genetic polymorphism on the metabolism and transport of atorvastatin

The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin: a meta-analysis.

The Effect of Slco1b1 Polymorphism on the Pharmacokinetics of Atorvastatin and 2-Hydroxyatorvastatin in Healthy Chinese People

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T Are Determinants of Inter-Subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers.

Influence of related genetic polymorphisms to pharmacokinetics and pharmacodynamics of Fluvastatin

Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients

Effect of OATP1B1 Genetic Polymorphism on the Uptake of Tamoxifen and Its Metabolite, Endoxifen.

[The Interactions Between Natural Products and OATP1B1].

Effect of CYP3A4 Gene Polymorphisms on Pharmacokinetic Characteristics of Atorvastatin Calcium after Food Intake

Genetic Polymorphisms and Function of the Organic Anion-Transporting Polypeptide 1A2 and Its Clinical Relevance in Drug Disposition

Study on the effect of the components of salviae miltiorrhizae on the metabolism of fluvastatin and its mechanism based on the polymorphism of cytochrome P450 2C9

Investigation of the Interactions Between Flavonoids and Human Organic Anion Transporting Polypeptide 1B1 Using Fluorescent Substrate and 3D-QSAR Analysis.

Population pharmacokinetic study of fluvastatin in patients with hyperlipemia

Genetic Polymorphisms of Human Hepatic OATPs: Functional Consequences and Effect on Drug Pharmacokinetics

[Effect of OATP1B1 521T --> C Heterogenesis on Pharmacokinetic Characterstics of Rosuvastatin in Chinese Volunteers].

Effect of SLCO1B1 Polymorphism on the Plasma Concentrations of Bile Acids and Bile Acid Synthesis Marker in Humans.

Advances in investigations of gene polymorphisms and drug-drug interactions mediated by organic anion transporting polypeptides OATP1B1 and OATP1B3

The Effect of Na+/taurocholate Cotransporting Polypeptide (NTCP) C.800c > T Polymorphism on Rosuvastatin Pharmacokinetics in Chinese Healthy Males.

Rifampicin Alters Atorvastatin Plasma Concentration on the Basis of SLCO1B1 521T>C Polymorphism